March 8, 2022 7:48am
Risk can be considered as bounces are due the oversold
Earnings: Voyager Therapeutics (VYGR)
Pre-open indications: 4 SELLs indications, 3 BUYs Indication and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Only the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.46% (+155 points), S&P futures are UP +0.54% (+23 points) and NASDAQ futures are UP +0.38% (+50 points)
Stock futures indicates a rebound open on Tuesday after being so down, it was time to come up,
European markets were fluctuating lower as investors monitor the war in Ukraine and Western responses,
Asia-Pacific markets edged lower as Mainland Chinese markets led declines across the board.
Henry’omics:
The pre-open action came after a deep dive where the S&P 500 dropped nearly 3% for its biggest one-day decline in more than a year. The Dow tumbled almost 800 points for its fifth negative session in six, while the Nasdaq slid 3.6%, being down 20% from its record high from November.
Time for an ascension and some “Hail Mary” moves
Economic data Docket: NFIB Small Business Optimism, Trade Balances, Wholesale Inventories and Wholesale trade sales
RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: the economic ramifications of disruption, selling into oversold conditions.” … https://www.regmedinvestors.com/articles/12330
Ebb and flow –
· March – 4 negative and 1 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... bluebird (BLUE) added - 22 total to date
Companies in my headlights – It’s your decision; I provide ideas and context based on pre-open indications:
BUY:
Intellia Therapeutics (NTLA) closed down -$2.18 after Friday’s -$5.93, Thursday’s -$13.42, Wednesday’s +$4.54 and last Tuesday’s -$19.00 with a positive +$0.14 or +0.22%
bluebird Bio (BLUE) closed down -$0.55 after Friday’s -$0.21 to $5.00 with a positive pre-open indication +$0.45 or +10.11% post earnings’ report, CFO loss and question of longevity.
Ionis Pharmaceuticals (IONS) closed down -$0.13 after Friday’s -$0.94 with a positive +$0.05 or +0.16% pre-open indication.
SELL:
Caribou Therapeutics (CRBU) closed up +$0.12 after Friday’s +$0.15 with a negative -$0.35 or -3.87% pre-open indication
Editas Medicine (EDIT) closed down -$0.06 after Friday’s -$0.68, Thursday’s -$0.41, Wednesday’s -$0.34 and last Tuesday’s +$0.37 with a negative pre-open indication of -$0.33 or -2.06%
Vericel (VCEL) closed down -$1.76 after Friday’s -$1.35 with a negative pre-open indication of -$1.88 or -4.99%
Sangamo Therapeutics (SGMO) closed up +$0.07 with a negative -$0.21 or -3.78% pre-open indication
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed up +$0.29 with 399 shares traded after Friday’s -$0.44 with 1,300 shares traded, Thursday’s +$0.25 with 487 shares traded, Wednesday’s +$0.34 with 649 shares traded, and last Tuesday’s -$0.04 with 4,359 shares traded …
- WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: Bounce, baby, bounce after four (4) negative closes; some relief needed.
Anything is wanted to signa a start of a new uptrend
I’d be “picking-up some equities (note above).
Earnings’ reporting on the horizon:
· Voyager Therapeutics - today
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
